🕒 Last update: loading…

Stock Ultragenyx Pharmaceutical Inc. RARE

Ultragenyx Pharmaceutical Inc. — Investlytic score 0/5 on the five criteria.

-
-
0/ 100
Score Investlytic · 5 criteria

Analysis in progress…

Investlytic score: 0/5 criteria met.

  • ❌ Price trend failed
  • ⚠️ Mixed growth
  • ❌ Debt failed
  • ❌ P/E failed
  • ❌ Correction failed

Price trend

Overall trend (8 years): insufficient progression (less than x1.5).

Price change 2018 → 2019: -1.77%

Price change 2019 → 2020: 224.12%

Price change 2020 → 2021: -39.25%

Price change 2021 → 2022: -44.90%

Price change 2022 → 2023: 3.22%

Price change 2023 → 2024: -12.02%

Price change 2024 → 2025: -45.33%

Price change 2025 → 2026: 8.30%

Price change 2026 (year to date): 5.55%

Financial growth

Revenue CAGR (8 years): 44.37%

Earnings CAGR (8 years): N/A

Growth status: positive trend (>1%/yr) in revenue, earnings data insufficient/N/A.

Debt

Debt-to-equity ratio: 1276000000.00

Debt/equity > 0.5 (maximum threshold).

P/E (Price/Earnings)

P/E ratio: -2.61

P/E > 25.0 (maximum threshold).

Correction (6 months)

Current correction: 30.55% from the high over 6 months.

Excessive correction (> 20.0%).

WATCH
The stock is currently being evaluated.

Criteria of the Investlytic model

- / 5
🔒

Investlytic rating reserved for members

Score out of 100, model verdict (buy, watch, sell) and details of the 5 criteria · visible with a free account.

02

Price trend

Price & trend

Interactive chart →
Loading chart…

⚖️ Comparison with the market

All stocks →
StockP/EDette/FPRevenue growthRating
Ultragenyx Pharmaceutical Inc.–––🔒
ANI Pharmaceuticals, Inc.8.20.60+48.0 %★ 4/5
PolyPeptide Group AG100.80.38+11.8 %–
Clariane SE626.62.16+12.4 %–
Azenta, Inc.93.20.06+0.0 %–

Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.

03

Detailed analysis · Price trend

-

🔒

Reserved for members

Global model trend and annual price variations · visible with a free account.

04

Revenues & profits

Revenue and net income

🔒

Reserved for members

Chart of revenues and net income over 8 periods · real data, no estimates.

05

Financial indicators

🔒

Reserved for members

18 financial indicators analyzed by groups of criteria: valuation, profitability, growth, solidity, dividend, and momentum.

06

Annual financial statements

Fiscal yearRevenueNet income Net marginEPSRevenue growth
🔒

Reserved for members

Complete annual financial statements: revenue, net income, margin, and EPS over 8 fiscal years.

+

Key reported figures

Revenue, net income and net margin reported by Ultragenyx Pharmaceutical Inc. over the latest fiscal years.

Revenue
673 m USD
fiscal year 2025
Net income
-575 m USD
fiscal year 2025
Net margin
-85.4 %
fiscal year 2025
Average annual growth
+19.9 %
Revenue growth over 5 years
Market cap
1.6 bn USD
Fiscal yearRevenueNet incomeNet marginRevenue growth
2020271 m-187 m-68.8 %n/a
2021351 m-454 m-129.2 %+29.7 %
2022363 m-707 m-194.7 %+3.4 %
2023434 m-607 m-139.7 %+19.5 %
2024560 m-569 m-101.6 %+29.0 %
2025673 m-575 m-85.4 %+20.1 %

Amounts converted to USD. Source: published annual accounts, collected on 13/11/2026.

+

Accounts and financial health

Balance sheet and cash flow published by Ultragenyx Pharmaceutical Inc. over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).

Overview
fragile accounts
according to Altman Z, Piotroski and net debt
Altman Z-score
-5.64
risk zone (below 1.81)
Piotroski Score
2 / 9
0 to 3: fragile accounts
Net Debt / EBITDA
-2.48 x
net cash
Fiscal year20212022202320242025
Cash and investments740 m748 m577 m610 m693 m
Total Debt42.0 m31.6 m43.2 m40.3 m1.3 bn
Net Debt-266 m-101 m-170 m-133 m842 m
Equity923 m352 m275 m255 m-80.0 m
Total assets1.5 bn1.5 bn1.5 bn1.5 bn1.5 bn
Operating cash flow-339 m-380 m-475 m-414 m-466 m
Investments (capex)73.1 m116 m44.3 m7.5 m6.0 m
Free cash-flow-412 m-527 m-522 m-422 m-472 m
Share buybacks00000
Dividends paid00000

Amounts in USD, currency of the published accounts.

Trailing 12-month ratios

Price / earnings (P/E)-3.13 x
Price / book value-4.42 x
Return on Equity (ROE)213.2 %
Return on Invested Capital (ROIC)-52.7 %
Net margin-71.8 %
Debt / equity-3.15 x
Current ratio1.40 x
Interest coverage-5.71 x
Free cash-flow yield-26.6 %

Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 16/11/2026.

+

Analyst consensus and forecasts

What the financial analysts covering Ultragenyx Pharmaceutical Inc. publish: ratings, price targets and earnings forecasts.

Majority rating
buy
34 analysts
Average price target
32.00 USD
from n/a to n/a, 44 targets over 12 months
Gap with the share price
+107.4 %
price 15.43 USD on 06/11/2026

Breakdown of ratings

strong buy 0buy 21hold 12sell 1strong sell 0

Average target over the last 3 months: 32.00 USD (22 targets).

Track record against expectations: reported EPS above consensus 5 times over the last 12 releases.

Source: ratings and forecasts published by analysts, collected on 14/11/2026. An analyst rating or target is not a guarantee.

+

Who owns the stock

Free float, institutional investors, large funds, executives and elected officials: declared positions in Ultragenyx Pharmaceutical Inc.

Large funds tracked
22
hold the stock as of 2026Q2
Executives (insiders)
0 / 5
0 purchases, 5 sales in 130 days
US elected officials
3
3 purchases, 0 sales in 12 months

Large funds tracked

FundSharesValue (USD)Weight in the fundChangeQuarter
State Street12.3 m411 m0.0 %+145.3 %2026Q2
BlackRock10.7 m356 m0.0 %+46.0 %2026Q2
Vanguard Group10.3 m236 m0.0 %+1.3 %2025Q4
AQR Capital Management6.6 m214 m0.1 %+43.3 %2026Q2
Two Sigma Investments3.6 m121 m0.1 %+64.2 %2026Q2
Geode Capital Management2.6 m86.1 m0.0 %+39.4 %2026Q2
D. E. Shaw & Co1.7 m57.8 m0.0 %+37.2 %2026Q2
Adage Capital Partners1.6 m52.8 m0.1 %+229.2 %2026Q2

Latest insider transactions

DatePersonSideAmount
15/10/2026Horn Howardsale107,898 USD
15/09/2026Huizenga Theodore Alansale17,410 USD
03/09/2026Huizenga Theodore Alansale2,252 USD
03/08/2026Parschauer Karah Herdmansale47,348 USD
03/08/2026Horn Howardsale117,024 USD

Elected officials' disclosures

DateOfficialSideAmount
29/09/2026Gilbert Cisnerospurchase$1,001 - $15,000
03/03/2026Gilbert Cisnerospurchase$1,001 - $15,000
18/02/2026Gilbert Cisnerospurchase$1,001 - $15,000

Sources: 13F filings (quarter shown), executives' Form 4 filings and US Congress members' disclosures, collected on 16/11/2026. Detailed disclosure obligations mainly apply to companies listed in the United States.

+

PEA and practical information

PEA eligibility
no
head office outside the EU and EEA
Listing exchange
Nasdaq
IPO: 31/01/2014
ISIN code
US90400D1081
Workforce
1,294
full-time employees
Chief executive
Emil D. Kakkis

Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.

?

Frequently asked questions about Ultragenyx Pharmaceutical Inc.

What is the Ultragenyx Pharmaceutical Inc. share price?

Latest recorded price: 16.08 USD on 13/11/2026, for a market cap of 1.6 bn USD.

What is the revenue of Ultragenyx Pharmaceutical Inc.?

673 m USD for fiscal year 2025, with net income of -575 m USD (net margin -85.4 %).

What do analysts say about Ultragenyx Pharmaceutical Inc.?

Out of 34 analysts: 21 buy or strong buy, 12 hold, 1 sell or strong sell. Average price target: 32.00 USD, i.e. +107.4 % from the share price.

Is Ultragenyx Pharmaceutical Inc. stock eligible for the French PEA?

No: the company is headquartered outside the European Union and the European Economic Area (ISIN US90400D1081).

How many employees does Ultragenyx Pharmaceutical Inc. have?

1,294 full-time employees according to the latest published profile.

Who runs Ultragenyx Pharmaceutical Inc.?

Emil D. Kakkis is the company's chief executive.

Which large funds own Ultragenyx Pharmaceutical Inc.?

As of 2026Q2, among the large funds tracked: State Street, BlackRock, Vanguard Group, AQR Capital Management, Two Sigma Investments.

07

Similar stocks